The acquisition is a strategic pipeline expansion into a rare disease with high unmet need and commercial precedent (Jynarque's $1.5B sales). With a clear development path starting in late 2026 and low upfront cost relative to potential upside, this could re-rate SCYX's valuation if early data is positive. Traders should monitor the Phase 2 initiation in Q4 2026 and watch for enrollment updates as catalysts.
Price Chart
Executive Summary
Scynexis (SCYX) announced the acquisition of PXL-770 (now SCY-770), a clinical-stage oral therapy for autosomal dominant polycystic kidney disease (ADPKD), from Poxel S.A. The deal includes an $8 million upfront payment, $8 million in potential development milestones, and up to $180 million in commercial milestones. SCY-770, a novel AMPK activator with orphan drug designation, is expected to enter a Phase 2 proof-of-concept study in Q4 2026, positioning Scynexis to expand into a high-unmet-need rare disease market.
Key Financial Metrics
Key Facts
- Scynexis acquired SCY-770 (formerly PXL-770) from Poxel S.A. for $8M upfront and up to $196M in total milestones ($8M development + $180M commercial).
- SCY-770 is a novel, oral, direct AMPK activator with orphan drug designation for ADPKD, a rare genetic kidney disease with limited treatment options.
- Phase 2 proof-of-concept study in ADPKD patients expected to start in Q4 2026, with early efficacy readout in second half of 2027.
- Current ADPKD market has only one approved therapy (Jynarque), which had ~$1.5B in U.S. sales in 2024 despite limited uptake.
- Scynexis has potential to receive up to $146M in annual sales milestones and low-to-mid-single-digit royalties from GSK on Brexafemme.
Financial Impact
$8 million upfront cash payment, $8 million in potential development milestones, and up to $180 million in commercial milestones based on sales performance
Risk Factors
- SCY-770 is still pre-clinical for ADPKD; efficacy in this indication is unproven despite prior safety data in NAFLD.
- Scynexis has limited cash resources; future funding needs could lead to dilution.
- Milestones are contingent on clinical and commercial success — high risk given early stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265277 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $4.70 $4.45 | ▼ −5.32% | ▼ −4.82% | $5.12 (+8.94%) |
Jun 26, 2026 14w ago | 8-K | $3.87 $4.73 | ▲ +22.22% | ▲ +20.83% | $5.12 (+32.30%) |
May 22, 2026 19w ago | 8-K | $5.45 $5.33 | ▼ −2.17% | ▼ −3.25% | $5.12 (−6.02%) |
May 11, 2026 20w ago | Press Release | $6.24 $5.26 | ▲ +15.77% | ▲ +15.17% | $5.12 (+17.95%) |
Apr 20, 2026 23w ago | 8-K | $8.48 $7.89 | ▼ −6.98% | ▼ −8.06% | $5.12 (−39.62%) |
Mar 31, 2026 26w ago | Press Release | $7.34 $7.97 | ▲ +8.62% | ▲ +4.67% | $5.12 (−30.21%) |
Mar 4, 2026 30w ago | Press Release | $6.34 $7.12 | ▲ +12.34% | ▲ +14.58% | $5.12 (−19.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access